KSQ Therapeutics, a Cambridge, Mass.-based biotechnology that uses the genetic-engineering tool CRISPR to develop new drugs, has raised $80 million, it’s second big raise in as many years. KSQ raised $76 million last October.
CRISPR-Based Drugmaker Raises $80 Million
